Lifeboat Foundation

CRISPR/Cas systems have undergone tremendous advancement in the past decade. These precise genome editing tools have applications ranging from transgenic crop development to gene therapy and beyond. And with their recent development of CRISPR-COPIES, researchers at the Center for Advanced Bioenergy and Bioproducts Innovation (CABBI) are further improving CRISPR’s versatility and ease of use.

“CRISPR-COPIES is a tool that can quickly identify appropriate chromosomal integration sites for genetic engineering in any organism,” said Huimin Zhao, CABBI Conversion Theme Leader and Steven L. Miller Chair of Chemical and Biomolecular Engineering (ChBE) at the University of Illinois. “It will accelerate our work in the metabolic engineering of non-model yeasts for cost-effective production of chemicals and biofuels.”

Gene editing has revolutionized scientists’ capabilities in understanding and manipulating genetic information. This form of genetic engineering allows researchers to introduce new traits into an organism, such as resistance to pests or the ability to produce a valuable biochemical.

The authors of a recent review published in Ageing Research Reviews summarize the research on epigenetic reprogramming and its potential as a rejuvenation therapy [1].

Aging leads to changes in the epigenome. Those changes can lead to alterations in gene regulation, affecting cellular homeostasis, and can play a role in age-associated phenotypes. Epigenetic modifications, the addition or removal of chemical groups to the DNA or DNA-associated proteins, have a profound impact on gene expression, tissue functions, and identity [2].

This review’s authors believe epigenetic reprogramming to be among the most currently promising interventions to stop or delay aging, potentially even reversing it at the cellular level. They believe that epigenetics are the basis of aging; therefore, being able to impact the epigenome would allow them to address multiple Hallmarks of Aging simultaneously.

City of Hope, one of the largest cancer research and treatment organizations in the United States, treated the oldest person to be cured of a blood cancer and then achieve remission for HIV after receiving a blood stem cell transplant from a donor with a rare genetic mutation. Research published in the New England Journal of Medicine today demonstrates that older adults with blood cancers who receive reduced intensity chemotherapy before a stem cell transplant with donor cells that are resistant to HIV may be cured of HIV infection.

Paul Edmonds, 68, of Desert Springs, California, is the fifth person in the world to achieve remission for acute myelogenous leukemia and HIV after receiving stem cells with a rare genetic mutation, homozygous CCR5 Delta 32. That mutation makes people who have it resistant to acquiring HIV. Edmonds is also the person who had HIV the longest—for over 31 years—among these five patients.

Continue reading “Case study features successful treatment of the oldest patient to achieve remission for leukemia and HIV” »

Summary: Researchers uncovered the mechanisms by which oxytocin (OXT) influences learning and memory in animals. Their study utilized pharmacogenetic techniques to activate specific OXT neurons within the brain, assessing the impact on cognitive functions through tasks like the Novel Object Recognition Task (NORT).

The findings reveal that activating OXTergic neurons significantly enhances long-term object recognition memory, with notable activity observed in the brain’s supramammillary nucleus (SuM) and dentate gyrus. This groundbreaking research not only deepens our understanding of oxytocin’s role beyond social bonding but also suggests its potential in developing treatments for dementia.

In the realm of scientific innovation, the past decade has seen the CRISPR/Cas systems emerge as a groundbreaking tool in genome editing, boasting applications that span from enhancing crop yields to pioneering gene therapy.

The recent advent of CRISPR-COPIES by the Center for Advanced Bioenergy and Bioproducts Innovation (CABBI) marks a significant leap forward, refining CRISPR’s flexibility and user-friendliness.

CRISPR-COPIES represents a cutting-edge solution designed to swiftly pinpoint ideal chromosomal sites for genetic modification across any species.

Plasminogen deficiency, a rare disorder characterized by impaired fibrinolysis, frequently results in ligneous conjunctivitis. In this report, we report a case of a Saudi girl manifesting both conjunctivitis and hydrocephalus. Her initial symptoms at 1 month of age were recurring eye redness, which was inaccurately diagnosed as simple conjunctivitis. Surgical intervention for her ocular lesions revealed underlying membrane deposition. She later exhibited signs of increased intracranial pressure, resulting in a hydrocephalus diagnosis and subsequent surgery. Genetic analysis confirmed the presence of plasminogen deficiency. Clinical evaluations highlighted ligneous conjunctivitis, variations in visual acuity, and facial acne. Laboratory assessments demonstrated diminished plasminogen levels.

“Aging reversal is something that’s been proven about eight different ways in animals,” geneticist George Church says. So when will humans get to turn back t…

After years of trials, Iowa State genetic scientists can build a DNA structure that can express its own genetic instructions, which could lead to medical advances.

Patients with recurrent Escherichia coli bacteremia can harbor strains with mutations that promote multidrug antibiotic resistance:

Certain patients with gram-negative bacterial bloodstream infections (GNB-BSIs) are well-known to experience recurrent bacteremia after receiving antimicrobial therapy — but is this phenomenon due to microbial factors? Researchers have analyzed isolates from patients with relapsed GNB-BSIs in which the initial and subsequent strains were nearly identical genetically.

Paired bacteremic isolates of E. coli, Klebsiella species, Serratia marcescens, and Pseudomonas aeruginosa were identified for a detailed analysis of the E. coli strains. Time-kill studies found that 4 of the 11 recurrent isolates had a higher number of bacterial colony-forming units persisting through 24 hours of exposure to meropenem. The recurrent strain with the greatest number of persisting cells had a loss-of-function mutation in the ptsI gene (involved in the phosphoenolpyruvate phosphotransferase system and shown in vitro to be important to the effects of bactericidal antibiotics). Challenging mice with the initial and ptsI mutant recurrent strains in a bacteremia model showed that both variants were equally virulent, but the recurrent strain was 10-fold less susceptible to treatment with ertapenem.

Continue reading “Real-World Development of” »